On August 9, 2022, STAT News shared insights from AFAR Scientific Director Nir Barzilai, MD, emphasizing the importance of funding the AFAR-managed TAME Trial to achieve an indication for aging from the Federal Food and Drug Administration (FDA).
In addition to serving as AFAR’s Scientific Director, Dr. Barzilai is a 1994 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar, a 2010 Irving S. Wright Award of Distinction recipient, and the Director at the Institute for Aging Research and distinguished Professor at the Albert Einstein College of Medicine.
Read the article, “As Billionaires Race to Fund Anti-Aging Projects, a Much-Discussed Trial Goes Overlooked,” here.
